Clinical Trial Update: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of derazantinib in FGFR2-altered intrahepatic cholangiocarcinoma and related conditions completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Hepatocellular and Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Derazantinib (derazantinib)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-12-19